Daniela E. Matei
Melvin and Bren Simon Cancer Center
Indiana University
Bloomington
Indiana 46202
USA
Name/email consistency: high
- Epigenetic resensitization to platinum in ovarian cancer. Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W.A., Huang, T., Nephew, K.P. Cancer Res. (2012)
- Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer. Shao, M., Hollar, S., Chambliss, D., Schmitt, J., Emerson, R., Chelladurai, B., Perkins, S., Ivan, M., Matei, D. Mol. Cancer Ther. (2012)
- Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. Matei, D., Sill, M.W., Lankes, H.A., DeGeest, K., Bristow, R.E., Mutch, D., Yamada, S.D., Cohn, D., Calvert, V., Farley, J., Petricoin, E.F., Birrer, M.J. J. Clin. Oncol. (2011)
- Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Matei, D.E., Nephew, K.P. Gynecol. Oncol. (2010)
- Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study. Matei, D., Miller, A.M., Monahan, P., Gershenson, D., Zhao, Q., Cella, D., Champion, V.L., Williams, S.D. J. Clin. Oncol. (2009)
- Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Matei, D., Schilder, J., Sutton, G., Perkins, S., Breen, T., Quon, C., Sidor, C. Gynecol. Oncol. (2009)
- Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial. Matei, D., Emerson, R.E., Schilder, J., Menning, N., Baldridge, L.A., Johnson, C.S., Breen, T., McClean, J., Stephens, D., Whalen, C., Sutton, G. Cancer (2008)
- Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Satpathy, M., Cao, L., Pincheira, R., Emerson, R., Bigsby, R., Nakshatri, H., Matei, D. Cancer Res. (2007)
- PDGF BB induces VEGF secretion in ovarian cancer. Matei, D., Kelich, S., Cao, L., Menning, N., Emerson, R.E., Rao, J., Jeng, M.H., Sledge, G.W. Cancer Biol. Ther. (2007)
- Novel agents in ovarian cancer. Matei, D. Expert. Opin. Investig. Drugs (2007)
- The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells. Matei, D., Satpathy, M., Cao, L., Lai, Y.C., Nakshatri, H., Donner, D.B. J. Biol. Chem. (2007)
- Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Matei, D., Emerson, R.E., Lai, Y.C., Baldridge, L.A., Rao, J., Yiannoutsos, C., Donner, D.D. Oncogene (2006)
- Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Matei, D., Chang, D.D., Jeng, M.H. Clin. Cancer Res. (2004)